FOI Request
- Disclosure ID
- FOI/03459
- Request Date
- December 13, 2019
- Subject
- Cancer Treatments
- Description
1). Within your health trust how many patients are currently [within the past 3 months] being treated with the following for breast cancer ?
Abemaciclib + aromatase inhibitor *
Abemaciclib + Fulvestrant
Alpelisib + Fulvestrant
Atezolizumab
Bevacizumab
Eribulin
Everolimus + Exemestane
Fulvestrant as a single agent
Gemcitabine + paclitaxel
Lapatinib
Neratinib
Olaparib
Palbociclib + aromatase inhibitor*
Pertuzumab + trastuzumab + docetaxel
Ribociclib + aromatase inhibitor*
Ribociclib + Fulvestrant
Talazoparib
Herceptin SC
Herceptin IV
Transtuzumab biosimilar SC
Transtuzumab biosimilar IV
Trastuzumab emtansine
Other active systemic anti-cancer therapy **
*aromatase inhibitor eg. Anastrozole, Exemestane or Letrozole
**eg. docetaxel, vinorelbine or capecitabine as a single agent.2). How many patients are being treated for
a. Neo-adjuvant breast cancer;
Transtuzumab total SC
Transtuzumab total IV
b. Adjuvant breast cancer;
Transtuzumab total SC
Transtuzumab total IV
3). In the past 3 months, how many Urothelial cancer patients were treated with;
Atezolizumab
Carboplatinum in combination with another agent
Carboplatinum single agent
Cisplatinum in combination with another agent
Cisplatinum single agent
Nivolumab
Pembrolizumab
Any other chemo regimen without cisplatinum or carboplatinum
Other active systemic anti-cancer therapy [please state]
Palliative care only
- Response
1). Please see accompanying document attachment 1
2). Please see accompanying document attachment 1
3). Currently our Trust does not have a standalone Urothelial diagnosis as it just comes under Urology which is broken down by Bladder/Prostate etc.
Please see accompanying document attachment 2